These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33524563)

  • 1. Inhibitory efficiency of potential drugs against SARS-CoV-2 by blocking human angiotensin converting enzyme-2: Virtual screening and molecular dynamics study.
    Khan AA; Baildya N; Dutta T; Ghosh NN
    Microb Pathog; 2021 Mar; 152():104762. PubMed ID: 33524563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
    Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
    J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spike protein recognizer receptor ACE2 targeted identification of potential natural antiviral drug candidates against SARS-CoV-2.
    Pokhrel S; Bouback TA; Samad A; Nur SM; Alam R; Abdullah-Al-Mamun M; Nain Z; Imon RR; Talukder MEK; Tareq MMI; Hossen MS; Karpiński TM; Ahammad F; Qadri I; Rahman MS
    Int J Biol Macromol; 2021 Nov; 191():1114-1125. PubMed ID: 34592225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation.
    Gorla US; Rao K; Kulandaivelu US; Alavala RR; Panda SP
    Comb Chem High Throughput Screen; 2021; 24(6):879-890. PubMed ID: 32819226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19.
    Gurung AB; Ali MA; Lee J; El-Zaidy M; Aljowaie RM; Almutairi SM
    PLoS One; 2022; 17(6):e0268919. PubMed ID: 35657783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.
    Prashantha CN; Gouthami K; Lavanya L; Bhavanam S; Jakhar A; Shakthiraju RG; Suraj V; Sahana KV; Sujana HS; Guruprasad NM; Ramachandra R
    J Mol Graph Model; 2021 Jan; 102():107769. PubMed ID: 33152616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
    Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
    Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potential target endoribonuclease NSP15 inhibitors of SARS-COV-2 from natural products through high-throughput virtual screening and molecular dynamics simulation.
    Hu LC; Ding CH; Li HY; Li ZZ; Chen Y; Li LP; Li WZ; Liu WS
    J Food Biochem; 2022 May; 46(5):e14085. PubMed ID: 35128681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of New Hydroxyethylamine Analogs against 3CL
    Kumar S; Sharma PP; Shankar U; Kumar D; Joshi SK; Pena L; Durvasula R; Kumar A; Kempaiah P; Poonam ; Rathi B
    J Chem Inf Model; 2020 Dec; 60(12):5754-5770. PubMed ID: 32551639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-COV-2.
    Muhseen ZT; Hameed AR; Al-Hasani HMH; Ahmad S; Li G
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33525411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phytoconstituents from Moringa oleifera fruits target ACE2 and open spike glycoprotein to combat SARS-CoV-2: An integrative phytochemical and computational approach.
    Siddiqui S; Ahmad R; Alaidarous M; Zia Q; Ahmad Mir S; Alshehri B; Srivastava A; Trivedi A
    J Food Biochem; 2022 May; 46(5):e14062. PubMed ID: 35043973
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Pandey AK; Verma S
    Drug Dev Ind Pharm; 2022 Oct; 48(10):539-551. PubMed ID: 36250723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fruit Bromelain-Derived Peptide Potentially Restrains the Attachment of SARS-CoV-2 Variants to hACE2: A Pharmacoinformatics Approach.
    Tallei TE; Fatimawali ; Adam AA; Elseehy MM; El-Shehawi AM; Mahmoud EA; Tania AD; Niode NJ; Kusumawaty D; Rahimah S; Effendi Y; Idroes R; Celik I; Hossain MJ; Emran TB
    Molecules; 2022 Jan; 27(1):. PubMed ID: 35011492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach.
    Mishra CB; Pandey P; Sharma RD; Malik MZ; Mongre RK; Lynn AM; Prasad R; Jeon R; Prakash A
    Brief Bioinform; 2021 Mar; 22(2):1346-1360. PubMed ID: 33386025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
    Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
    Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2).
    Zeng MS; Yu WD; Wang HX; Liu JY; Xu PP
    Int J Biol Macromol; 2021 Jul; 183():2248-2261. PubMed ID: 34111482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
    Cetin A
    Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of potential inhibitors against SARS-CoV-2 endoribonuclease: RNA immunity sensing.
    Al-Rashedi NAM; Munahi MG; Ah ALObaidi L
    J Biomol Struct Dyn; 2022 Jul; 40(11):4879-4892. PubMed ID: 33357040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.